Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -85.48% is 15% above its 5-year average of -100.69%, near the high end of its 5-year range (-351.99%–16.85%).
As of the fiscal period ended Tuesday, June 30, 2026. 45.56% above its 12-month average of -157.04%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -85.48%.
RETURN ON EQUITY (ROE)
-85.48%
RETURN ON EQUITY (ROE) AVG TTM
-157.04%
RETURN ON EQUITY (ROE) AVG 3Y
-125.92%
RETURN ON EQUITY (ROE) AVG 5Y
-100.69%
RETURN ON EQUITY (ROE) AVG 10Y
-185.49%
RETURN ON EQUITY (ROE) AVG 15Y
-201.71%
RETURN ON EQUITY (ROE) AVG 20Y
-142.47%
CURRENT VS TTM AVG
+45.56%
CURRENT VS 3Y AVG
+32.11%
CURRENT VS 5Y AVG
+15.10%
CURRENT VS 10Y AVG
+53.91%
CURRENT VS 15Y AVG
+57.62%
CURRENT VS 20Y AVG
+40.00%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-103.49%
vs the sector median at left
ProMIS Neurosciences, Inc.
Market Cap
$82.59M
Return on Equity (ROE)
-85.48%
TTM Avg
-157.04%
3Y Avg
-125.92%
5Y Avg
-100.69%
Market Cap
$82.53M
Return on Equity (ROE)
-116.74%
TTM Avg
-1373.57%
3Y Avg
-759.05%
5Y Avg
-574.01%
Market Cap
$82.47M
Return on Equity (ROE)
-150.95%
TTM Avg
-77.89%
3Y Avg
-62.90%
5Y Avg
-47.80%
Market Cap
$82.29M
Return on Equity (ROE)
232.78%
TTM Avg
-18.33%
3Y Avg
-28.65%
5Y Avg
-29.96%
Market Cap
$81.22M
Return on Equity (ROE)
-28.85%
TTM Avg
-24.95%
3Y Avg
-20.92%
5Y Avg
-19.20%
Market Cap
$81.20M
Return on Equity (ROE)
-130.67%
TTM Avg
-143.13%
3Y Avg
-106.90%
5Y Avg
-90.63%
Market Cap
$84.13M
Return on Equity (ROE)
-50.80%
TTM Avg
-124.86%
3Y Avg
-88.30%
5Y Avg
-60.21%
Market Cap
$80.30M
Return on Equity (ROE)
-309.44%
TTM Avg
-515.53%
3Y Avg
-464.77%
5Y Avg
-329.14%
Market Cap
$79.61M
Return on Equity (ROE)
-85.65%
TTM Avg
-57.41%
3Y Avg
-45.73%
5Y Avg
-8.61%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProMIS Neurosciences, Inc. (PMN) | $82.59M | -85.48% | -157.04% | -125.92% | -100.69% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.53M | -116.74% | -1373.57% | -759.05% | -574.01% |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | -150.95% | -77.89% | -62.90% | -47.80% |
| LENSAR Inc (LNSR)vs › | $82.29M | 232.78% | -18.33% | -28.65% | -29.96% |
| MediciNova, Inc. (MNOV)vs › | $81.22M | -28.85% | -24.95% | -20.92% | -19.20% |
| Nutriband Inc. (NTRB)vs › | $81.20M | -130.67% | -143.13% | -106.90% | -90.63% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | -50.80% | -124.86% | -88.30% | -60.21% |
| Humacyte, Inc. (HUMA)vs › | $80.30M | -309.44% | -515.53% | -464.77% | -329.14% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | -85.65% | -57.41% | -45.73% | -8.61% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | -105.20% | -53.79% | -41.98% | -32.71% |
ROE
-85.5%
ROA
-74.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -85.48% |
| 2026-03-31 | -66.89% |
| 2025-09-30 | -318.73% |
| 2025-03-31 | -9.86% |
| 2024-12-31 | 16.85% |
| 2024-09-30 | -7.75% |
| 2023-12-31 | -351.99% |
| 2023-09-30 | -183.47% |
| 2022-06-30 | -87.62% |
| 2022-03-31 | -107.52% |
| 2021-12-31 | -157.01% |
| 2021-09-30 | -100.10% |
| 2019-03-31 | -865.92% |
| 2018-12-31 | -814.22% |
| 2018-09-30 | -142.50% |
| 2018-06-30 | -86.76% |
| 2018-03-31 | -320.99% |
| 2017-12-31 | -362.67% |
| 2017-09-30 | -224.83% |
| 2017-03-31 | -255.20% |
| 2016-09-30 | -247.48% |
| 2016-06-30 | -609.83% |
| 2016-03-31 | -306.57% |
| 2015-12-31 | -299.84% |
| 2015-09-30 | -171.05% |
| 2012-09-30 | -400.15% |
| 2012-06-30 | -220.81% |
| 2011-09-30 | -229.57% |
| 2011-06-30 | -108.41% |
| 2011-03-31 | -123.03% |
| 2010-12-31 | -133.94% |
| 2010-09-30 | -118.85% |
| 2010-06-30 | -174.38% |
| 2010-03-31 | -94.22% |
| 2009-12-31 | -73.67% |
| 2009-09-30 | -62.50% |
| 2009-06-30 | -64.09% |
| 2009-03-31 | -130.40% |
| 2008-12-31 | -123.74% |
| 2008-09-30 | -100.18% |
| 2008-06-30 | -94.83% |
| 2008-03-31 | -81.38% |
| 2007-12-31 | -61.83% |
| 2007-09-30 | -48.45% |
| 2007-06-30 | -37.10% |
| 2007-03-31 | -30.88% |
| 2006-12-31 | -59.77% |
| 2006-09-30 | -50.41% |
| 2006-06-30 | -53.73% |
| 2006-03-31 | -46.05% |
